♥ HF Guideline NavigatorESC 2026

10 › 10.8

10.8 Frailty

Pages 68–69 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 68 · PDF

10.7. Anxiety, depression, and cognitive impairment

these medications require more caution and should be started at low doses after consideration of the risks and benefits, with close monitoring for signs of airway obstruction, and appropriate supervision.897 Chronic obstructive pulmonary disease exacerbations should not be a cause of beta-blocker discontinuation.898 Inhaled corticosteroids and beta-adrenergic agonists have not been specifically studied in patients with HF; however, they do not seem to increase CV risk.899,900 In addition, appropriate management of COPD can improve cardiac function.901 Sleep-disordered breathing is found in over one-third of patients with HF and is even more prevalent in DHF. Sleepdisordered breathing includes OSA, central sleep apnoea (CSA), and mixed disease. SDB negatively impacts disease progression and prognosis.902,903 Patients with a suspicion of SDB should be referred for overnight polysomnography to definitively diagnose SDB, and to document the predominant type of sleep apnoea (central vs obstructive).902 The therapeutic approach to SDB includes the correction of underlying causes, when identified. The use of adaptive servo-ventilation (ASV) in patients with HFrEF and predominantly CSA is not recommended, based on the results of the SERVE-HF trial,904 which showed an increase in both all-cause and CV death in patients with chronic HF, LVEF ≤45%, and SDB with predominant CSA.904 The ADVENT-HF trial randomized 731 patients with HF, LVEF ≤45%, and coexisting SDB, mostly OSA (73%) to standard optimal treatment alone or standard optimal treatment and ASV (1:1). Over a mean follow-up period of 3.6 years, ASV had a neutral effect on the primary composite outcome (the cumulative incidence of all-cause death, first CV hospitalization, new-onset AF/flutter, and delivery of an appropriate ICD shock).905 However, ASV improved sleep quality and structure, health-related QoL, and symptoms of patients with SDB.905 Thus, in patients with SDB and predominant OSA, nocturnal hypoxaemia can be treated with nocturnal oxygen supplementation, continuous positive airway pressure (CPAP), bilevel positive airway pressure, and ASV. When SDB is caused by CSA, implantable phrenic nerve stimulation was found to be safe and effective in reducing the apnoea–hypopnoea index in a small RCT.906–908

10.8. Frailty Frailty is defined as a multidimensional, dynamic, and potentially reversible state, related to, but independent of, age, that makes individuals more vulnerable to the effects of stressors and at increased risk of poor outcomes. A score assessing frailty including four domains (clinical, functional, psychocognitive, and social) has recently been proposed.918 The presence of frailty might have an impact on disease management and is associated with higher rates of death and hospitalizations, and reduced health-related QoL, regardless of which tool was used to assess frailty.919–923 In patients with HF, frailty is particularly prevalent in older adults. When frailty is suspected or identified, a multidisciplinary approach to facilitate an individualized management is warranted.918,922,924

Recommendation Table 20 — Recommendations for lung disease and sleep-disordered breathing (see Evidence Table 89) Recommendations

Anxiety and depression are common findings in patients affected by chronic and disabling conditions, such as HF, and need to be promptly identified to minimize psychological distress and its negative consequences.909 Depression affects 20% of patients with HF, and it may affect adherence to FMT. Its prevalence is higher in women, and it is associated with worse clinical status and poorer prognosis.910–912 The diagnosis of depression typically relies on standardized questionnaires and clinical interviews. Symptom overlap between HF and depression can complicate diagnosis, as both conditions may present with cognitive issues (e.g. difficulty concentrating) and physical symptoms (e.g. fatigue). Several validated questionnaires are available for screening clinically significant depressive symptoms911 (see Supplementary data online, Section S7.4, Table S23). Cognitive impairment in these patients has been reported.911,913 However, there is still no consensus on the best therapy for patients with HF and depression. Cognitive behavioural therapy has demonstrated significant favourable long-term (4–9 months) reduction of anxiety and depression and improvement in QoL compared with nontreated patients.914,915 The safety of sertraline and escitalopram has been demonstrated, although without a significant reduction in depression compared with placebo.916,917 Tricyclic antidepressants should be avoided for the treatment of depression in HF as they may cause hypotension, WHF, and arrhythmias.911,912

Adaptive servo-ventilation may be considered in

Recommendation Table 21 — Recommendations for anxiety, depression, and frailty (see Evidence Tables 90 and 91)

apnoea to improve sleep quality, health-related QoL and symptoms.905

Adaptive servo-ventilation is not recommended III

apnoea because of an increased risk of CV and all-cause death.

Assessment of anxiety, depression and frailty

CV, cardiovascular; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life. a Class of recommendation. b Level of evidence.

in patients with HFrEF and sleep-disordered breathing with predominant central sleep

should be considered in patients with HF to support the development of personalized care plans and to identify factors that may contribute to adverse outcomes.909,914,915,920,923 HF, heart failure. a Class of recommendation. b Level of evidence.

patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep

Page 69 · PDF

10.9. Other non-cardiovascular comorbidities Infections may cause WHF and can precipitate HFH.925,926 Infections should ideally be prevented or, if present, promptly recognized and treated to avoid disease progression.927–930 Influenza vaccination is associated with a reduced risk of pneumonia and all-cause death in patients with HF.931–936 Thus, influenza and pneumococcal vaccination should be considered in all patients with HF in order to reduce the risk of infection-related complications.935 Thyroid dysfunction can cause changes in cardiac function and structure and may precipitate DHF.937,938 Assessment of thyroid function is recommended in patients with de novo HF or DHF and should be regularly assessed during follow-up of patients with HF. Treatment of thyroid dysfunction should be guided by endocrine guidelines.939–942 Hyperuricaemia and consequent gout attacks can be frequent in patients with HF, mainly caused or precipitated by diuretic treatment.943,944 Allopurinol is recommended as the first choice to chronically reduce uric acid levels in patients with HF,945 whereas colchicine can be used for acute gout attacks. Non-steroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors are not recommended in patients with HF because they may precipitate decompensation and worsen kidney function.942,946–948 Heart failure and erectile dysfunction frequently coexist.949,950 Cardioselective beta-blockers should be preferred in patients with HF and erectile dysfunction, mainly bisoprolol and nebivolol, started at the lowest doses.897 In the presence of erectile dysfunction symptoms, phosphodiesterase-V inhibitors are generally safe and can be considered in patients who are compensated,951 avoiding their concomitant use with nitrates.952 Recommendation Table 22 — Recommendations for other non-cardiovascular comorbidities (see Evidence Tables 92 and 93)

Influenza and pneumococcal vaccination should be considered in patients with HF to reduce the risk of pneumonia complications,

Recommendation Table 23 — Recommendations for the multidisciplinary management of heart failure (see Evidence Tables 94–96)

hospitalization, and death.

NSAIDs and COX-2 inhibitors are not recommended in patients with HF as they increase the risk of HF worsening and

HFH.942,946–948 COX-2, cyclooxygenase-2; HF, heart failure; HFH, heart failure hospitalization; NSAID, non-steroidal anti-inflammatory drug. a Class of recommendation. b Level of evidence.

11. Multidisciplinary team management, long-term follow-up, and patient care 11.1. Multidisciplinary management of heart failure Multidisciplinary care for HF combines the expertise of various professionals to provide integrated, patient-centred care that

Recommendations A multidisciplinary HF management programme is recommended in patients with HF to reduce the risk of HFH and

death.964–967 HF education and self-management strategies in patients with HF are recommended to reduce the risk of HFH or death.977 Multidisciplinary interventions to improve adherence, including assessment of health literacy and polypharmacy review, are recommended in patients with HF to reduce the risk of hospitalization and death.978–981 HF, heart failure; HFH, heart failure hospitalization. a Class of recommendation. b Level of evidence.

improves both clinical outcomes and QoL for patients (Figure 21). Access to healthcare professionals with awareness of HF and expertise in its diagnosis and management is essential for early detection and better outcomes. Multidisciplinary HF care involves generalist and specialist healthcare professionals,955 including cardiologists, cardiothoracic surgeons, specialist nurses, pharmacists, and physiologists (Figure 21) (see Supplementary data online, Section S8.1).17,956–963 Management by an HF multidisciplinary team (HF-MDT) across outpatient and inpatient settings improves outcomes for people with HF.962,964–967 The literature evaluates various methods of delivering HF management programmes enabling local HF services to design services tailored to their HF-MDT and the structure of their healthcare system. A meta-analysis of 16 RCTs with 3999 eligible patients evaluating the benefits of multidisciplinary HF clinics compared with usual care demonstrated a reduction in HFH.967 A meta-analysis of eight RCTs with 1764 patients indicated that multidisciplinary teams may have the potential to reduce death, although a definitive RCT is needed.964 The benefits were more evident in patients with a recent emergency department presentation or HFH.966 Other methods of delivery, including home visits and transitional care models, are given in Supplementary data online, Section S8.1.145,962,965,968–972 Healthcare professionals involved in the management of HF, whether specialist or generalist, should be equipped with the knowledge required to effectively assess and manage HF through appropriate education and training.958,973,974 Malnutrition has been associated with worse prognosis in patients with HF.738 Thus, nutritional assessment and dietary interventions can be useful.588,589 No evidence supports fluid restriction in chronic HF.975,976